These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 4188117

  • 21. Progressive supranuclear palsy.
    Hynd GW, Pirozzolo FJ, Maletta GJ.
    Int J Neurosci; 1982 Mar; 16(2):87-98. PubMed ID: 6762362
    [Abstract] [Full Text] [Related]

  • 22. [An autopsy case of progressive supranuclear palsy with special reference to the distribution of Alzheimer's neurofibrillary changes in the basal ganglia and brain stem of two cases of this disease (author's transl)].
    Ishino H, Hikichi A, Morita H.
    Seishin Shinkeigaku Zasshi; 1975 Apr 25; 77(4):245-57. PubMed ID: 1242811
    [No Abstract] [Full Text] [Related]

  • 23. Progressive supranuclear palsy. Clinical and pharmacologic update.
    Jankovic J.
    Neurol Clin; 1984 Aug 25; 2(3):473-86. PubMed ID: 6398402
    [Abstract] [Full Text] [Related]

  • 24. [Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases].
    Dubas F, Gray F, Escourolle R.
    Rev Neurol (Paris); 1983 Aug 25; 139(6-7):407-16. PubMed ID: 6612148
    [Abstract] [Full Text] [Related]

  • 25. [Case of progressive supranuclear palsy with involvement of spinal anterior horns].
    Mrozek K, Kamińska A, Marciniak M.
    Neurol Neurochir Pol; 1972 Aug 25; 6(4):631-5. PubMed ID: 5086758
    [No Abstract] [Full Text] [Related]

  • 26. Familial progressive supranuclear palsy.
    Gazeley S, Maguire JA.
    Clin Neuropathol; 1996 Aug 25; 15(4):215-20. PubMed ID: 8836606
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.
    Mendell JR, Engel WK, Chase TN.
    Lancet; 1970 Mar 21; 1(7647):593-4. PubMed ID: 4190545
    [No Abstract] [Full Text] [Related]

  • 31. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
    Levin SL.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972 Mar 21; 72(9):1418-26. PubMed ID: 4349303
    [No Abstract] [Full Text] [Related]

  • 32. [Progressive supranuclear ophtalmoplegia. (Steele-Richardon-Olszewski syndrome). New anatomo-clinical case].
    Rouzaud M, Degiovanni E, Jobard P, Gray F, Durand JP.
    Rev Neurol (Paris); 1974 Mar 21; 130(3-4):143-64. PubMed ID: 4445658
    [No Abstract] [Full Text] [Related]

  • 33. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A.
    Brux Med; 1972 Oct 21; 52(10):673-80. PubMed ID: 4656191
    [No Abstract] [Full Text] [Related]

  • 34. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy.
    Boelmans K, Holst B, Hackius M, Finsterbusch J, Gerloff C, Fiehler J, Münchau A.
    Mov Disord; 2012 Mar 21; 27(3):421-7. PubMed ID: 22290788
    [Abstract] [Full Text] [Related]

  • 35. L-dopa in Parkinson's syndrome.
    Poskanzer DC.
    N Engl J Med; 1969 Feb 13; 280(7):382-3. PubMed ID: 5764823
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [L-Dopa therapy of the Parkinson syndrome].
    Poeck K.
    Dtsch Med Wochenschr; 1971 Mar 05; 71(10):436. PubMed ID: 5545293
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M.
    Psychiatr Neurol Neurochir; 1971 Mar 05; 74(4):331-3. PubMed ID: 5146239
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.